Vanda Pharmaceuticals (VNDA) Net Income towards Common Stockholders (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$48.5 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 64.52% year-over-year to -$48.5 million; the trailing twelve-month figure through Mar 2026 stood at -$239.5 million (down 441.44% YoY), and the FY2025 full-year result was -$220.5 million, down 1066.53% from the prior year.
• Net Income towards Common Stockholders climbed to -$48.5 million in Q1 2026, from -$141.2 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $6.9 million in Q4 2022 to a low of -$141.2 million in Q4 2025.
• A 5-year average of -$16.4 million and a median of -$4.5 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders jumped 149.94% in 2023 and slumped 4000.73% in 2024, its largest moves.
• Tracing VNDA's Net Income towards Common Stockholders over 5 years: stood at $6.9 million in 2022, then sank by 134.85% to -$2.4 million in 2023, then slumped by 103.93% to -$4.9 million in 2024, then plunged by 2795.55% to -$141.2 million in 2025, then jumped by 65.63% to -$48.5 million in 2026.
• Business Quant data shows VNDA's Net Income towards Common Stockholders at -$48.5 million in Q1 2026, -$141.2 million in Q4 2025, and -$22.6 million in Q3 2025.